NCT06837077View on ClinicalTrials.gov

Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

March 14, 2025

Primary Completion Date

June 30, 2025

Study Completion Date

July 31, 2025

Conditions
Hypercholesterolemia and Hyperlipidemia
Interventions
DRUG

SHR-1209 single-site subcutaneous injection

SHR-1209 single-site subcutaneous injection.

DRUG

SHR-1209 multiple-site subcutaneous injections

SHR-1209 multiple-site subcutaneous injections.

Trial Locations (1)

230000

The First Affiliated Hospital of USTC, Hefei

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT06837077 - Study of SHR-1209 Administered by Single-site or Multiple-site Subcutaneous Injections in Healthy Volunteers | Biotech Hunter | Biotech Hunter